过表达Snail增强肺癌细胞A549的体外侵袭能力

用锌指转录因子Snail诱导肺癌细胞A549发生上皮细胞-间质转化(epithelial-mesenchymal transition,EMT),检测肺癌发生EMT后细胞侵袭能力的变化,为临床筛选分子靶向药物提供依据.构建pcDNA3.1-snail载体,用pcDNA3.1-snail及空pcDNA3.1载体转染肺癌A549细胞后,进行G418筛选;光镜观察培养后细胞形态学的改变、免疫细胞化学与免疫荧光检测细胞表达E-钙黏着蛋白(E-cadherin)、波形蛋白(vimentin)的改变,Western印迹检测细胞中E-钙黏着蛋白和波形蛋白的改变,Transwell侵袭小室法进行细胞体外侵袭能力检测.采用pcDNA3.1-snail转染细胞后,A549细胞变得细长,细胞融合度降低.免疫细胞化学、免疫荧光、Western印迹结果显示,E-钙黏着蛋白表达降低,波形蛋白表达升高;transwell侵袭小室法结果显示,过表达Snail的A549细胞穿透matrigel胶的细胞数明显增多.结果提示,Snail能有效诱导肺癌发生EMT,并且能增强肺癌的体外侵袭能力.     

MiR-186-5p通过靶向调控PTTG1抑制肺腺癌细胞的上皮-间质转化

先前研究表明,miR-186-5p在人类许多恶性肿瘤中扮演抑癌基因的作用,但其在肺腺癌上皮-间质转化（epithelial-mesenchymal transition,EMT）中的作用并不明确。本研究旨在证明,miR-186-5p可通过靶向调控PTTG1抑制肺腺癌细胞的上皮-间质转化。我们首先分析了miR-186-5p在人肺癌细胞中的表达。荧光定量PCR（QRT-PCR）结果显示,与人正常肺上皮细胞BEAS-2B相比,肺腺癌细胞SPC-A1、A549中的miR-186-5p表达量明显降低。为研究miR-186-5p在肺腺癌细胞中的功能,利用GV369-miR-186-5p表达载体,实现了在A549细胞中的过表达。基因转染结合Transwell侵袭结果显示,与对照质粒转染的A549细胞相比,过表达miR-186-5p的A549细胞的体外侵袭能力明显下降。Western印迹检测细胞中EMT相关标志物揭示,GV369-miR-186-5p转染的A549细胞中的上皮-钙黏着蛋白（E-cadherin）表达明显上调,而神经-钙黏着蛋白（N-cadherin）和波形蛋白（vimentin）表达明显下调。同时,GV369-miR-186-5p转染引起其靶基因--垂体肿瘤转化基因1（pituitary tumor-transforming gene 1,PTTG1）编码蛋白在A549细胞中明显降低。重要的是,过表达miR-186-5p与敲减PTTG1均可导致上皮-钙黏着蛋白表达上调,而神经-钙黏着蛋白和波形蛋白下调|而miR-186-5p和PTTG1表达载体共转染后,3种EMT相关标志物在A549的表达与对照细胞的表达无明显差异,提示过表达PTTG1可抵消miR-186-5p对EMT相关标志物表达的影响。综上所述,miR-186-5p可通过靶向调控PTTG1抑制EMT的发生,进而抑制肺腺癌细胞的侵袭转移。     

Nupr1调控非小细胞肺癌细胞迁移、凋亡机制的研究

目的:探讨核蛋白1(Nupr1)调控非小细胞肺癌细胞迁移、凋亡机制的研究。方法:肿瘤抑制剂盐酸素(salinomycin)不同时间处理非小细胞肺癌细胞A549后采用Western Blot法检测非小细胞肺癌细胞A549中Cleaved Caspase-3、Nupr1的蛋白表达;Transwell小室检测Nupr1基因沉默后非小细胞肺癌细胞A549细胞体外迁移、侵袭能力的变化;Western Blot法检测Nupr1沉默后非小细胞肺癌细胞A549 MMP-2、TIMP-1的蛋白表达;流式细胞仪检测Nupr1沉默后非小细胞肺癌细胞A549的凋亡情况。结果:与未经肿瘤抑制剂salinomycin处理对照组相比较,salinomycin处理后的非小细胞肺癌细胞A549中Nupr1蛋白表达量下降,Cleaved Caspase-3蛋白表达量升高,并且随着作用时间呈依赖关系。Nupr1-siRNA转染组的迁移能力相比对照组未转染组下降(64.4±7.2)%,Nupr1-siRNA转染组的侵袭能力相比对照组下降(58.7±7.3)%。与未转染Nupr1-siRNA对照组相比较,转染后TIMP-1的表达明显上调,而MMP-2的表达则明显下调。流式细胞仪检测结果显示Nupr1沉默后非小细胞肺癌细胞A549出现大量凋亡。结论:Nupr1基因沉默后通过上调TIMP-1的表达,下调MMP-2的表达降低肺癌A549细胞的侵袭和迁移能力,进而促进非小细胞肺癌细胞凋亡。     

shRNA沉默HuR抑制肝细胞癌细胞系SMMC-7721的增殖、迁移及侵袭能力

人抗原R (human antigen R,HuR)基因在肺癌、乳腺癌等多种肿瘤组织中高表达。推测HuR基因也参与肝癌的发展过程。为探索HuR对肝细胞癌细胞系SMMC-7721的增殖、迁移和侵袭的作用,本研究通过蛋白质印迹实验,检测HuR在肝细胞癌细胞系和正常肝细胞中蛋白质的表达水平。结果显示,肝细胞癌细胞系SMMC-7721 HuR的表达量显著高于正常肝细胞HL-7702。合成特异性靶向HuR基因的shRNA,转染肝细胞癌细胞系SMMC-7721,检测结果发现,HuR基因表达量下调90%。沉默HuR,实时细胞分析技术(real time cell analysis,RTCA)结果显示,细胞增殖能力降低55%,侵袭能力下降75%;细胞划痕实验结果显示,迁移能力下降80%;克隆形成实验中细胞克隆数减少85%;此外,在HuR敲低稳转肝细胞癌细胞系SMMC-7721细胞中过表达Bcl-2,其细胞学现象部分获得逆转。激光共聚焦扫描系统检测结果显示,Bcl-2主要定位于肝细胞癌细胞系SMMC-7721的核膜及胞质。蛋白质印迹法检测结果显示,沉默HuR,Bcl-2下调92%,Survivin下调55%,Twinst1下调69%,N-钙黏着蛋白(N-cadherin)下调48%,E-钙黏着蛋白(E-cadherin)上调1.5倍。以上结果表明,HuR可能通过调控定位于核膜及胞质上的Bcl-2来参与肝细胞癌细胞系SMMC-7721的增殖、迁移、侵袭及克隆形成过程,HuR基因有望成为临床上治疗肝癌的一个新的潜在靶点。     

PHD1通过下调NF-κB介导的cyclinD1的表达抑制肺癌细胞的生长和增殖

目的:探讨PHD1在肺癌中的功能,并进一步研究其分子机制,为肺癌的治疗寻找新的靶点。方法:选取人肺癌细胞A549,以脂质体为载体一方面过表达PHD1,另一方面合成设计靶向PHD1的siRNA沉默PHD1,利用荧光素酶检测NF-κB的活性,分别用western blot和real-time PCR检测cyclinD1的表达水平。在A549细胞中过量稳定表达带GFP标记的PHD1,流式细胞仪检测细胞周期变化,测量细胞的生长曲线,并将细胞注射到裸鼠皮下观察其成瘤情况。结果:过表达PHD1可明显抑制NF-κB的活性和IκBα的降解,降低cyclin D1的mRNA和蛋白表达水平;而干扰PHD1的表达可显著增加NF-κB的活性,并上调cyclin D1的mRNA和蛋白表达水平,而不影响cyclinE1。过表达IκBαSR可以阻止干扰PHD1引起的cyclinD1 mRNA水平的上调。过表达PHD1可引起细胞周期的停滞,显著抑制细胞的增殖和移植瘤的生长。结论:PHD1可能通过下调NF-κB介导的cyclinD1的表达抑制肺癌细胞的生长和增殖。     

特异性下调葡萄糖调节蛋白78表达对肝细胞癌侵袭和转移能力的影响

为了研究特异性下调葡萄糖调节蛋白(Grp)78对肝细胞癌侵袭和转移能力的影响。通过小干扰RNA(siRNA)技术特异性下调人肝细胞癌细胞株BEL7402中Grp78的表达,并应用Transwell法和划痕法对肝细胞癌侵袭、转移能力的改变进行分析,应用免疫沉淀技术和GST-pulldown技术分别对黏着斑激酶(FAK)的磷酸化水平和小GTPase RhoA的活性进行研究,应用免疫印迹技术检测E-钙黏着蛋白、N-钙黏着蛋白和波形蛋白的表达。结果发现,Transwell实验和划痕实验结果显示特异性下调Grp78表达可以抑制肝细胞癌的侵袭和转移,免疫沉淀结果显示特异性下调Grp78表达可以降低FAK的磷酸化水平,GST-pulldown实验结果表明特异性下调Grp78表达可以上调RhoA的活性。免疫印迹实验结果表明特异性下调Grp78可以下调N-钙黏着蛋白、波形蛋白的表达,上调E-钙黏着蛋白的表达。结果表明特异性下调Grp78在体外可以抑制肝细胞癌的侵袭和转移,这种抑制作用是通过FAK脱磷酸化和抑制肿瘤的上皮-间叶转化实现的。     

LRP16基因通过雌激素受体α介导抑制Ishikawa细胞中E-钙黏着素的转录活性

目的:既往研究表明LRP16基因过表达通过下调E-钙黏着素促进子宫内膜癌Ishikawa细胞的侵袭生长,本研究目的在于探讨LRP16基因下调E-钙黏着素的分子途径。方法:用免疫组化方法检测LRP16基因过表达的Ishikawa细胞中E-钙黏着素的表达;用共转染与荧光素酶实验检测LRP16基因对E-钙黏着素启动子转录活性的影响;用染色质免疫共沉淀实验检测雌激素受体α(ERα)与LRP16蛋白在E-钙黏着素启动子区的招募状况。结果:E-钙黏着素在LRP16过表达的Ishikawa细胞中的表达水平明显下调;LRP16抑制了E-钙黏着素启动子的转录活性,该效应呈现对雌激素(E2)存在的依赖性特征;LRP16本身没有与E-钙黏着素启动子区结合,但明显抑制了ERα与E-钙黏着素启动子区的结合。结论:LRP16通过抑制ERα对E-钙黏着素基因的转录激活活性,下调E-钙黏着素在Ishikawa细胞中的表达水平。     

沉默ABCE1对神经胶质瘤细胞U251增殖、迁移和凋亡的影响

ABCE1是ATP结合盒蛋白亚家族成员之一,在病毒感染,细胞增殖,抗凋亡,翻译起始和核糖体生物发生等过程中有重要的作用。为了探讨ABCE1对神经胶质瘤细胞U251增殖、迁移和凋亡的作用,本研究通过实时荧光定量PCR和免疫印迹实验检测ABCE1在神经胶质瘤细胞和正常胶质细胞中的mRNA和蛋白质表达水平,结果发现ABCE1在神经胶质瘤细胞U251中的表达高于在正常胶质细胞中的表达。利用siRNA靶向沉默ABCE1后,神经胶质瘤细胞U251中ABCE1 mRNA和蛋白的表达水平均显著减少,细胞的凋亡率显著提高,细胞增殖和迁移明显受到抑制,而且细胞对化疗药物替莫唑胺的敏感性增强。此外,沉默ABCE1后,Bcl-2的mRNA和蛋白质表达水平显著下调,而Bax的mRNA和蛋白质表达水平显著上调。以上研究结果表明,ABCE1与神经胶质瘤细胞的增殖和迁移密切相关,通过siRNA靶向沉默ABCE1基因可显著降低U251细胞的增殖和迁移能力。     

TRPM7的表达水平与肺癌发生发展的关系

为了解TRPM7在肺癌中的表达及其与肺癌进展的关系,本研究检测了TRPM7在非小细胞肺癌患者肺癌组织样本和相邻正常肺泡组织样本中的表达,以及TRPM7在人肺腺癌A549细胞系和人支气管上皮细胞系16HBE中的表达。通过转染shRNA敲低肺癌细胞中的TRPM7,并应用TRPM7拮抗剂Waixenicin A处理细胞。免疫组化染色和Western blotting分析显示,与正常肺泡组织样本中的TRPM7表达相比,TRPM7在肺癌样本中显著高表达。TRPM7的表达水平与癌症分期有关,分期越高,TRPM7的表达水平越高。TRPM7在A549细胞中的表达强度显著高于16HBE细胞。细胞集落形成测定结果显示,沉默TRPM7会显著抑制细胞集落形成的能力。SRB细胞活力测定显示,沉默TRPM7会显著抑制细胞活力。沉默TRPM7显著降低了肺癌细胞的迁移(-68.94%)和侵袭(-68.84%)能力。沉默TRPM7显著抑制了热休克蛋白90α(HSP90α)、尿激酶型纤溶酶原激活剂(uPA)和基质金属蛋白酶2 (MMP2)的表达。Waixenicin A显著抑制了肺癌细胞的活力及Hsp90α/uPA/MMP2信号分子的表达。另外,Waixenicin A显著降低了肺癌细胞的迁移(-65.35%)和侵袭(-71.85%)能力。本研究表明,TRPM7的异常表达通过激活Hsp90α/uPA/MMP2信号通路来提高人肺癌细胞的活力和转移能力。研究结果表明,靶向TRPM7的抑制剂可能是治疗肺癌的有效药物。     

长链非编码RNA PCGEM1促进胰腺癌细胞增殖和迁移

该文的目的为探讨长链非编码RNA PCGEM1(long non-coding RNA PCGEM1,lnc RNAPCGEM1)对胰腺癌细胞增殖和迁移的影响。通过荧光定量PCR检测三种胰腺癌细胞以及人胰腺癌组织和癌旁组织中PCGEM1的表达水平,分别在Bx PC3和Pa Tu8988细胞中转染p CDH-PCGEM1及其空载质粒p CDH,在SW1990细胞中转染si RNA和其对照si RNA,分别上调或下调PCGEM1在不同胰腺癌细胞中的表达;细胞克隆形成、CCK-8实验检测细胞增殖能力;Transwell实验检测细胞迁移能力;Western blot法检测MMP2、MMP9和E-钙黏着蛋白的蛋白表达以及荧光定量PCR检测MMP2和MMP9水平。结果表明,PCGEM1差异性表达于三种胰腺癌细胞中,其中SW1990表达水平相对较高,Bx PC3和Pa Tu8988表达水平相对较低。胰腺癌组织中PCGEM1水平高于癌旁组织。过表达PCGEM1后,细胞增殖和迁移能力增强,MMP2和MMP9的蛋白质水平增加,E-钙黏着蛋白的蛋白质水平降低;相反,降低PCGEM1表达,细胞增殖和迁移能力减弱,MMP2和MMP9的蛋白质水平降低,E-钙黏着蛋白的蛋白质水平升高。由此说明,lnc RNA PCGEM1可促进胰腺癌细胞的增殖和迁移。     

Over-expression of LSD1 promotes proliferation, migration and invasion in non-small cell lung cancer

Background

Lysine specific demethylase 1 (LSD1) has been identified and biochemically characterized in epigenetics, but the pathological roles of its dysfunction in lung cancer remain to be elucidated. The aim of this study was to evaluate the prognostic significance of LSD1 expression in patients with non-small cell lung cancer (NSCLC) and to define its exact role in lung cancer proliferation, migration and invasion.

Methods

The protein levels of LSD1 in surgically resected samples from NSCLC patients were detected by immunohistochemistry or Western blotting. The mRNA levels of LSD1 were detected by qRT-PCR. The correlation of LSD1 expression with clinical characteristics and prognosis was determined by statistical analysis. Cell proliferation rate was assessed by MTS assay and immunofluorescence. Cell migration and invasion were detected by scratch test, matrigel assay and transwell invasion assay.

Results

LSD1 expression was higher in lung cancer tissue more than in normal lung tissue. Our results showed that over-expression of LSD1 protein were associated with shorter overall survival of NSCLC patients. LSD1 was localized mainly to the cancer cell nucleus. Interruption of LSD1 using siRNA or a chemical inhibitor, pargyline, suppressed proliferation, migration and invasion of A549, H460 and 293T cells. Meanwhile, over-expression of LSD1 enhanced cell growth. Finally, LSD1 was shown to regulate epithelial-to-mesenchymal transition in lung cancer cells.

Conclusions

Over-expression of LSD1 was associated with poor prognosis in NSCLC, and promoted tumor cell proliferation, migration and invasion. These results suggest that LSD1 is a tumor-promoting factor with promising therapeutic potential for NSCLC.     

B-Myb稳定过表达H1299细胞株的构建与分析

B—Myb是Myb家族的成员之一,在细胞周期和癌变过程中具有重要作用。但其在肺癌中的作用及其分子机制仍不清楚。为了研究B—Myb在肺癌中的作用,构建了B-Myb稳定过表达的H1299肺癌细胞株。流式细胞术和MTT检测的结果表明,B—Myb稳定过表达导致G1期细胞减少,S期细胞增加进而促进细胞增殖：克隆形成实验及Transwell的结果表明,B—Myb稳定过表达显著增强H1299细胞的克隆形成、侵袭及迁移能力。定量RT-PCR检测结果表明,B—Myb稳定过表达显著提高了细胞周期基因CCNA1的表达水平;对CD97和MTSS1等细胞运动相关下游基因的表达则无明显影响。该研究成功构建了B-Myb稳定过表达细胞株,发现了B-Myb过表达可促进肺癌细胞的增殖、侵袭迁移及克隆形成能力,为进一步研究奠定了基础。     

KIF26B在非小细胞肺癌发生发展过程中的表达与功能研究

驱动蛋白与肿瘤的发生有密切联系，但对 KIF26B驱动蛋白在非小细胞肺癌的表达和相关功能作用的研究甚少。为了探索KIF26B在非小细胞肺癌中的表达水平及潜在机制，通过干扰KIF26B后探索对非小细胞肺癌增殖、侵袭、迁移、细胞周期、凋亡以及相关蛋白表达量的影响。对mRNA TCGA 数据库信息分析得出，KIF26B基因在非小细胞肺癌中高表达。qRT-PCR 检测 KIF26B在几株常见非小细胞肺癌细胞系中的表达水平，筛选出 KIF26B在A549 和 NCI-H292细胞系中高表达。利用 RNA干扰技术(RNA interference, RNAi)敲低 A549 和 NCI-H292细胞的 KIF26B基因，通过CCK8、采用实时细胞分析仪、平板克隆及 Transwell 实验检测敲低 KIF26B基因后的生物学功能，免疫印迹法检测蛋白表达水平。结果显示，敲低KIF26B后A549 和 NCI-H292细胞增殖明显降低，侵袭及迁移能力明显减弱。敲低KIF26B后阻碍了A549 和 NCI-H292细胞从G1期向S期的转变，同时凋亡细胞明显增多，与之相关的细胞周期蛋白 D1、Bcl-2、E-cadherin和Vimentin的表达水平显著下调，同时活化的半胱天冬酶-3（active Caspase-3）和其剪切底物 PARP1 的剪切体（cleaved PARP1）表达水平显著上调。结果表明KIF26B可能作为非小细胞肺癌发生的促癌基因，参与了非小细胞肺癌的发生及发展过程。KIF26B有望成为非小细胞肺癌治疗的潜在靶点。     

Combination therapy with KRAS siRNA and EGFR inhibitor AZD8931 suppresses lung cancer cell growth in vitro

Lung cancer is a leading cause of cancer-related deaths worldwide, with less than a 5-year survival rate for both men and women. Epidermal growth factor receptor (EGFR) and Kirsten rat sarcoma oncogene (KRAS) signaling pathways play a critical role in the proliferation and progression of various cancers, including lung cancer. Genetic studies have shown that amplification, over-expression, or mutation of EGFR is an early and major molecular event in many human tumors. KRAS mutation is a negative factor in various cancer, including non-small-cell lung cancer, and complicates therapeutic approaches with adjuvant chemotherapy and anti-EGFR directed therapies. This article is dedicated to evaluating the synergistic effect of a novel EGFR inhibitor AZD8931 and KRAS small interfering RNA (siRNA) on the proliferation and apoptosis of lung adenocarcinoma cancer cells. A549 lung cancer cells were treated with KRAS siRNA and the EGFR inhibitor alone or in combination. The cytotoxic effects of KRAS siRNA and te EGFR inhibitor were determined usingMTT assay, and induction of apoptosis was determined by FACS analysis. Suppression of KRAS, Her-2, and EGFR expression by treatments was measured by qRT-PCR and western blotting. KRAS siRNA and the EGFR inhibitor significantly reduced the proliferation of A549 cells as well as KRAS and EGFR mRNA levels 24 hr after treatment. The results also indicated that the silencing of KRAS and EGFR has synergistic effects on the induction of apoptosis on the A549 cells. These results indicated that KRAS and EGFR might play important roles in the progression of lung cancer and could be potential therapeutic targets for treatment of lung cancer.     

HSULF-1 inhibits ERK and AKT signaling and decreases cell viability in vitro in human lung epithelial cells

Background

Heparan sulfate proteoglycans (HSPGs) modulate the binding and activation of signaling pathways of specific growth factors, such as fibroblast growth factor-2 (FGF-2). Human endosulfatase 1 (HSULF-1) is an enzyme that selectively removes 6-O sulfate groups from HS side chains and alter their level and pattern of sulfation and thus biological activity. It is known that HSULF-1 is expressed at low levels in some cancer cell lines and its enhanced expression can inhibit cancer cell growth or induce apoptosis, but the mechanism(s) involved has not been identified.

Methods

HSULF-1 mRNA expression was assessed in five normal cells (primary human lung alveolar type 2 (hAT2) cells, adult lung fibroblasts (16Lu), fetal lung fibroblasts (HFL), human bronchial epithelial cells (HBE), and primary human lung fibroblasts (HLF)) and five lung cancer cell lines (A549, H292, H1975, H661, and H1703) using quantitative real time polymerase chain reaction (qRT-PCR). H292 and hAT2 cells over-expressing HSULF-1 were analyzed for cell viability, apoptosis, and ERK/Akt signaling, by MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay, TUNEL (Terminal deoxynucleotidyl transferase dUTP nick end labeling) assay, and Western Blot, respectively. Apoptosis pathway activation was confirmed by PCR array in hAT2, H292, and A549 cells.

Results

HSULF-1 was expressed at a significantly lower level in epithelial cancer cell lines compared to normal cells. Infection with recombinant adenovirus for HSULF-1 over-expression resulted in decreased cell viability in H292 cells, but not in normal hAT2 cells. HSULF-1 over-expression induced apoptosis in H292 cells, but not in hAT2 cells. In addition, apoptosis pathways were activated in both H292 and A549 cells, but not in hAT2 cells. HSULF-1 over-expression reduced ERK and Akt signaling activation in H292 cells, which further demonstrated its inhibitory effects on signaling related to proliferation.

Conclusions

These results indicate that HSULF-1 is expressed at lower levels in H292 lung cancer cells than in normal human alveolar cells and that its over-expression reduced cell viability in H292 cells by inducing apoptotic pathways, at least in part by inhibiting ERK/Akt signaling. We hypothesize that HSULF-1 plays important roles in cancer cells and functions to modify cell signaling, inhibit cancer proliferation, and promote cancer cell death.     

柚皮素通过Notch1/Hes1通路抑制肺癌干细胞增殖、迁移和分化

为探讨柚皮素对肺癌干细胞增殖、迁移和分化的分子机制,本研究应用免疫磁珠法分选肺癌干细胞(A549-CSCs),并通过流式细胞术进行表面分子的鉴定;通过CCK8法检测不同浓度的柚皮素(25μg/m L,50μg/mL, 100μg/mL)对肺癌干细胞(A549-CSCs)活力的影响,Transwell检测柚皮素对A549-CSCs细胞迁移能力的影响,Q-PCR检测柚皮素对肺癌干细胞分化相关因子Sox2和Oct4 m RNA表达的影响,Western blotting法检测柚皮素对细胞内Notch1和Hes1蛋白表达的影响。流式细胞术检测结果显示,A549-CSCs细胞表面分子CD133呈阳性表达,符合肺癌干细胞特征。CCK8结果显示,与对照组(control)比较,25μg/m L、50μg/mL、100μg/mL柚皮素处理A549-CSCs 24 h,细胞活力显著降低(p<0.05);Transwell检测结果显示,与对照组比较,不同浓度柚皮素处理组A549-CSCs迁移能力显著降低(p<0.05);定量PCR (real-time polymerase chain reaction, Q-PCR)结果显示,与对照组比较,柚皮素处理组细胞Sox2和Oct4 m RNA表达水平显著降低(p<0.05);蛋白质印迹法(Western blotting)结果显示,与对照组相比柚皮素处理组细胞Notch1和Hes1蛋白表达水平均降低。本研究发现柚皮素可能通过抑制Notch1/Hes1通路抑制肺癌干细胞增殖、迁移和分化。这为柚皮素治疗肺癌提供临床依据。     

miR-424-5p通过下调BCL-2的表达抑制人肺癌A549细胞增殖

microRNAs(miRNAs)是一类在真核生物中广泛存在的长度约为20～22个核苷酸的单链非编码小RNA,通过与其靶基因mRNA的3′非翻译区（3′UTR）结合发挥转录后抑制作用,参与调节细胞生长增殖、细胞代谢、细胞凋亡以及肿瘤的发生发展等过程。为研究microRNA-424-5p（miR-424-5p）在肺癌细胞中的作用及机理,利用lipo2000转染试剂将miR-424-5p mimics转染入人的非小细胞型肺癌细胞(NSCLC)A549中,流式细胞术检测A549细胞的周期变化及凋亡情况,发现细胞生长阻滞于G1/G0期且凋亡率显著上升。利用克隆形成实验和CCK-8法分别检测,发现miR-424-5p导致A549细胞增殖能力及活力降低。用在线数据库预测出抗凋亡基因BCL-2可能是miR-424-5p的靶基因,随后扩增BCL-2 mRNA 的3′UTR,采用双荧光素酶报告实验及Western印迹检测证明BCL-2确为miR-424-5p的靶基因。构建BCL-2的真核表达载体pCMV-HA-BCL-2,与空载分别转染A549细胞后发现过表达BCL-2可抵消miR-424-5p引起的细胞周期阻滞及细胞凋亡。以上结果提示,miR-424-5p可以通过下调BCL-2的表达来抑制肺癌细胞增殖。     

The clinical significance of UBE2C gene in progression of renal cell carcinoma

Renal cell carcinoma (RCC), with high morbidity and mortality, is one of the top ten serious cancers. Due to limited therapies and little knowledge about the mechanism underlying RCC, overall survival of RCC patients is poor. UBE2C is a member of ubiquitin modification system and promotes carcinogenesis in cancer, but its role in RCC is unknown. Based on the TCGA (The Cancer Genome Atlas) data, UBE2C was over-expressed in a total of 525 RCC tissues and displayed higher expression in advanced tissues (stage IV vs stage I, p<0.05). RT-qPCR and IHC analysis confirmed over-expression of UBE2C in 90 of clinical RCC tissues. Further, UBE2C was associated with clinical factors including TNM stage, gender, and pathological stage. And higher UBE2C expression predicted shorter overall survival and progression-free survival. Both univariate and multivariate COX analysis suggested UBE2C as a critical gene in RCC. Then GO and KEGG analysis showed that cell cycle and DNA replication pathways were two top signaling pathways affected by UBE2C. In vitro assay showed that knockdown of UBE2C in 786-O cells inhibited proliferation and migration significantly. Therefore, this study proves that UBE2C is an important gene in RCC and is essential to proliferation and migration of RCC.Key words: UBE2C, GO analysis, KEGG analysis, renal cell carcinoma     

肿瘤相关成纤维细胞对非小细胞肺癌恶性生物学行为影响

目的:探讨肿瘤相关成纤维细胞(Tancer Associated Fibroblast,TAF)对非小细胞肺癌(Non-small Cell Lung Cancer,NSCLC)恶性生物学行为的影响。方法:选取在本院肿瘤科住院手术的非小细胞肺癌患者,收集术后肺癌标本,马松三色染色(Masson Trichrome Stain)和天狼星红染色(Sirius Red Stain)观察肺癌组织(Lung Cancer Tissue,LCT)、癌旁组织(Pericarcinomatous Tissue,PCT)和正常组织(Normal Tissue,NT)中TAF的表达情况;体外将非小细胞肺癌细胞A549与非小细胞肺癌成纤维细胞P-gp共培养,CCK-8检测共培养前后A549细胞增殖能力;细胞划痕和Trans-well实验分别检测A549细胞迁移和侵袭能力;q RT-PCR和Western blot检测A549细胞上皮间质转化(Epithelial Mesenchymal Transition,EMT)标志蛋白E-cadherin、N-cadherin和Vimentin的表达。结果:Masson和Sirius染色结果显示:肺癌组织中纤维的表达明显高于癌旁组织;与P-gp共培养的A549细胞的增殖、迁移和侵袭能力及上皮间质转化相关蛋白N-cadherin和Vimentin表达均明显高于阴性对照组(P0.05),而E-cadherin的表达明显降低(P0.05)。结论:TAF可能通过诱导非小细胞肺癌细胞EMT的发生从而促进非小细胞肺癌的增殖、迁移和侵袭等恶性生物学行为。